Gapping down
In reaction to disappointing earnings/guidance: ANAD -9.6%, (lowers Q2 revenue guidance; announces restructuring), DD -3.7%, CMC -0.5%.
M&A news: NGHC -1.7% (announces acquisition of Imperial).
Select EU financial related names showing weakness: NBG -1.3%, SAN -0.9%, UBS -0.8%.
Other news: ISIS -3.5% (trading lower on negative blog mention), IG -2.6% (priced 4.65 mln shares of its common stock at $5.00/share), AMSG -1.7% (prices public offerings of common stock and Mandatory Convertible Preferred Stock, Series A-1), DOW -1% (following DD guidance), REGN -0.6% (announced that EYLEA (aflibercept) Injection has been recommended for approval by the European CHMP for the treatment of visual impairment due to diabetic macular edema), MON -0.5% (announces $4.5 bln debt issue), ALV -0.5% (reaches agreement in principle to settle Us Securities class action).
Analyst comments: BYD -1.6% (initiated with a Underperform at Buckingham Research), ENL -1.6% (downgraded to Equal-weight vs Overweight at Barclays), HFC -1.2% (downgraded to Neutral from Outperform at Credit Suisse), EC -0.9% (initiated with an Underweight at Barclays), UNH -0.7% (initiated with an Underperform at Sterne Agee), SSL -0.7% (downgraded to Equal Weight from Overweight at Barclays), COV -0.5% (downgraded to Outperform from Strong Buy at Raymond James).
In reaction to disappointing earnings/guidance: ANAD -9.6%, (lowers Q2 revenue guidance; announces restructuring), DD -3.7%, CMC -0.5%.
M&A news: NGHC -1.7% (announces acquisition of Imperial).
Select EU financial related names showing weakness: NBG -1.3%, SAN -0.9%, UBS -0.8%.
Other news: ISIS -3.5% (trading lower on negative blog mention), IG -2.6% (priced 4.65 mln shares of its common stock at $5.00/share), AMSG -1.7% (prices public offerings of common stock and Mandatory Convertible Preferred Stock, Series A-1), DOW -1% (following DD guidance), REGN -0.6% (announced that EYLEA (aflibercept) Injection has been recommended for approval by the European CHMP for the treatment of visual impairment due to diabetic macular edema), MON -0.5% (announces $4.5 bln debt issue), ALV -0.5% (reaches agreement in principle to settle Us Securities class action).
Analyst comments: BYD -1.6% (initiated with a Underperform at Buckingham Research), ENL -1.6% (downgraded to Equal-weight vs Overweight at Barclays), HFC -1.2% (downgraded to Neutral from Outperform at Credit Suisse), EC -0.9% (initiated with an Underweight at Barclays), UNH -0.7% (initiated with an Underperform at Sterne Agee), SSL -0.7% (downgraded to Equal Weight from Overweight at Barclays), COV -0.5% (downgraded to Outperform from Strong Buy at Raymond James).